What the FDA labels say about taking them together
Fosamprenavir and paroxetine
Fosamprenavir's FDA label of September 15, 2023 names paroxetine in its drug interactions section, and paroxetine's label names fosamprenavir too. The fosamprenavir label: “Any paroxetine dose adjustment should be guided by clinical effect.”
Check it at the source: the fosamprenavir FDA label on DailyMed (effective September 15, 2023, Mylan Pharmaceuticals Inc.); the paroxetine FDA label on DailyMed (effective February 12, 2026, Mylan Pharmaceuticals Inc.).
What does the fosamprenavir label say about paroxetine?
Fosamprenavir label, drug interactionsConcomitant Drug Class/Drug Name: Antidepressant: Paroxetine, trazodone; Effect on Concentration of Amprenavir or Concomitant Drug: ↓ Paroxetine; Clinical Comment: Any paroxetine dose adjustment should be guided by clinical effect (tolerability and efficacy).
Source: FDA drug label (Fosamprenavir Calcium), Mylan Pharmaceuticals Inc., effective September 15, 2023 (SPL set 3a1424d8-844c-4e24-9ebd-b2c2b61b61a3), via openFDA; the full label on DailyMed
What does the paroxetine label say about fosamprenavir?
Paroxetine label, drug interactionsClinical Impact; Co-administration of fosamprenavir/ritonavir with paroxetine tablets significantly decreased plasma levels of paroxetine.
Paroxetine Hydrochloride label (Apotex Corp, September 16, 2026), drug interactionsFosamprenavir/Ritonavir Clinical Impact Co-administration of fosamprenavir/ritonavir with paroxetine significantly decreased plasma levels of paroxetine. Intervention Any dose adjustment should be guided by clinical effect (tolerability and efficacy).
Brisdelle label (Legacy Pharma USA, Inc., April 28, 2025), drug interactionsConcomitant Drug Name: Fosamprenavir/Ritonavir; Effect of Concomitant Drug on Paroxetine: Decreased plasma concentration of paroxetine; Clinical Recommendations: Monitor clinical effect of BRISDELLE. No BRISDELLE dosage adjustment is needed.
Source: FDA drug label (Paroxetine Hydrochloride, NDA020936), Apotex Corp, effective September 16, 2026 (SPL set 087ff0d3-1761-47ea-a8c1-7c4cb679af97), via openFDA
Source: FDA drug label (Brisdelle, NDA204516), Legacy Pharma USA, Inc., effective April 28, 2025 (SPL set 502311b3-b617-4cbd-a3ab-a60f2c62880a), via openFDA
Source: FDA drug label (Paxil, NDA020031), Apotex Corp, effective October 22, 2024 (SPL set ef3b5cbe-f9e1-c1ac-79da-cfe14e3a7e7e), via openFDA
Source: FDA drug label (Paroxetine), Mylan Pharmaceuticals Inc., effective February 12, 2026 (SPL set 89dd7e24-85fc-4152-89ea-47ec2b48a1ed), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Fosamprenavir | Paroxetine | |
|---|---|---|
| Labeled for | HIV | Depression, Anxiety, Menopause symptoms |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | n/a | $0.0611 per tablet 20 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once